Arvinas Inc is a biotechnology company focused on developing innovative therapies using its proprietary protein degradation technology, which aims to target and eliminate disease-causing proteins within cells. The company works primarily in the fields of oncology and other severe diseases, harnessing the power of targeted protein degradation to create potentially transformative treatments that can address unmet medical needs. By leveraging its expertise in molecular biology and drug development, Arvinas strives to push the boundaries of traditional drug design and delivery, ultimately seeking to improve the lives of patients with challenging health conditions. Read More
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET.
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors –
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers –
– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader –
